Quince Therapeutics Inc's Customers Performance

Name: Quince Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

QNCX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


QNCX's Source of Revenues		• List of QNCX Customers

for the same period Quince Therapeutics Inc

• List of QNCX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Quince Therapeutics Inc's Comment on Sales, Marketing and Customers

The company faces risks related to employee misconduct and potential financial impairments from acquisitions, including those of EryDel and Novosteo. Additionally, its business is affected by unstable market conditions and global economic factors.

News about Quince Therapeutics Inc Contracts

Quince Therapeutics Unveils Advanced PK Modeling Study for Pioneering Ataxia-Telangiectasia Therapy with eDSP,

Empowering Therapeutics: Quince Therapeutics’ Advanced PK Modeling Study for Ataxia-Telangiectasia Treatment In a promising stride towards developing biologically attuned therapies for rare diseases, Quince Therapeutics recently announced the publication of a significant study in CPT: Pharmacometrics and Systems Pharmacology. This study elucidates the outcomes of an advanced population pharmacokinetic (PK) modeling analysis of their Phase 3 leading asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient’s own red blood cells). The intricate study highlights its applications in treating pediatric patients with Ataxia-Telangiectasia (A-T), a debilitating rare disease characterized by progres...

FDA Grants Fast Track Designation to Quince Therapeutics for EryDex System Targeting Ataxia-Telangiectasia ...

South San Francisco, Calif. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its innovative EryDex System. This decision aims to expedite the development and review of the EryDex System, specifically targeting patients suffering from Ataxia-Telangiectasia (A-T), a rare neurodegenerative disorder. Quince Therapeutics, a company focused on developing advanced drug delivery technologies, utilizes a patient s own biological systems to deliver therapeutics for rare diseases. The EryDex System incorporates dexamethasone sodium phosphate (DS or 0 0) as its active pharmaceutical ingredient, acti...

Quince Therapeutics Inc’s Comment on Sales, Marketing and Customers

QNCX's Stock Performance relative to it's Customers

QNCX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Quince Therapeutics Inc	183.99	0.00	78.29	38
SUBTOTAL	0.00	0.00	0.00	-

Sources: Quince Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Quince Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Quince Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.